Patents by Inventor Peter J. Schatz

Peter J. Schatz has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 6716811
    Abstract: Novel compounds are provided that bind to G-CSFR. The novel compounds have a peptide chain approximately 6 to 40 amino acids in length that binds to G-CSFR. The compounds are useful as probes for affinity screening. In addition, the compounds have demonstrated agonist or antagonist activity for the G-CSFR, and are therefore useful in treatment of diseases including patients who suffer from a low white blood cell titer. Pharmaceutical compositions and methods of use are provided as well.
    Type: Grant
    Filed: July 20, 2000
    Date of Patent: April 6, 2004
    Assignee: Affymax, Inc.
    Inventors: Steven E. Cwirla, Palani Balu, David J. Duffin, Sunila Piplani, Barbara McEowen Merrill, Peter J. Schatz
  • Publication number: 20030158116
    Abstract: Described are peptides and peptide mimetics that bind to and activate the thrombopoietin receptor. Such peptides and peptide mimetics are useful in methods for treating hematological disorders and particularly, thrombocytopenia resulting from chemotherapy, radiation therapy, or bone marrow transfusions as well as in diagnostic methods employing labeled peptides and peptide mimetics.
    Type: Application
    Filed: February 27, 2002
    Publication date: August 21, 2003
    Inventors: William J. Dower, Ronald W. Barrett, Steven E. Cwirla, David J. Duffin, Christian M. Gates, Sherril S. Haselden, Larry C. Mattheakis, Peter J. Schatz, Christopher R. Wagstrom, Nicholas C. Wrighton
  • Patent number: 6506362
    Abstract: Described are peptides and peptide mimetics that bind to and activate the thrombopoietin receptor. Such peptides and peptide mimetics are useful in methods for treating hematological disorders and particularly, thrombocytopenia resulting from chemotherapy, radiation therapy, or bone marrow transfusions as well as in diagnostic methods employing labeled peptides and peptide mimetics.
    Type: Grant
    Filed: April 10, 2001
    Date of Patent: January 14, 2003
    Assignee: Glaxo Group Limited
    Inventors: William J. Dower, Ronald W. Barrett, Steven E. Cwirla, Christian M. Gates, Peter J. Schatz, Palaniappan Balasubramanian, Christopher R. Wagstrom, Richard Wayne Hendren, Randolph B. Deprince, Surekha Podduturi, Qun Yin
  • Patent number: 6465430
    Abstract: Receptors are peptides and peptide mimetics that bind to and activate the thrombopoietin receptor. Such peptides and peptide mimetics are useful in methods for treating hematological disorders and particularly, thrombocytopenia resulting from chemotherapy, radiation therapy, or bone marrow transfusions as well as in diagnostic methods employing labeled peptides and peptide mimetics.
    Type: Grant
    Filed: April 13, 2000
    Date of Patent: October 15, 2002
    Assignee: SmithKline Beecham Corporation
    Inventors: William J. Dower, Ronald W. Barrett, Steven E. Cwirla, David J. Duffin, Christian M. Gates, Sherril S. Haselden, Larry C. Mattheakis, Peter J. Schatz, Christopher R. Wagstrom, Nicholas C. Wrighton
  • Patent number: 6410245
    Abstract: The invention provides methods for identifying agents that are ligands for nuclear receptors. The methods include conducting multiplexed assays utilizing positive hybrid systems, reverse hybrid systems, direct interaction assays and other assays to screen for ligands having activity with a receptor of interest. The methods can be performed in various multiplexing formats to produce a profile that can be used to categorize a test ligand relative to known agonists and antagonists.
    Type: Grant
    Filed: April 1, 1998
    Date of Patent: June 25, 2002
    Assignee: Affymax, Inc.
    Inventors: Jeffrey P. Northrop, Charles P. Hart, Peter J. Schatz
  • Patent number: 6309842
    Abstract: The invention provides methods for screening libraries of complexes for compounds having a desired property, especially, the capacity to agonize, bind to, or antagonize a cellular receptor. The complexes in such libraries comprise a compound under test, a tag recording at least one step in synthesis of the compound, and a tether susceptible to modification by a reporter molecule. Modification of the tether is used to signify that a complex contains a compound having a desired property. The tag can be decoded to reveal at least one step in the synthesis of such a compound.
    Type: Grant
    Filed: November 24, 1997
    Date of Patent: October 30, 2001
    Assignee: Glaxo Wellcome Inc.
    Inventors: William J. Dower, Christian M. Gates, Gregory L. Heinkel, Guy Lalonde, Larry C. Mattheakis, Christopher J. Paddon, Peter J. Schatz
  • Patent number: 6265552
    Abstract: Biotinylation peptides can be fused to other peptides or proteins of interest using recombinant DNA techniques to provide efficient methods for biotinylating the resulting fusion proteins in vivo or in vitro.
    Type: Grant
    Filed: February 24, 2000
    Date of Patent: July 24, 2001
    Assignee: Affymax Technologies N.V.
    Inventor: Peter J. Schatz
  • Patent number: 6251864
    Abstract: Described are peptides and peptide mimetics that bind to and activate the thrombopoietin receptor. Such peptides and peptide mimetics are useful in methods for treating hematological disorders and particularly, thrombocytopenia resulting from chemotherapy, radiation therapy, or bone marrow transfusions as well as in diagnostic methods employing labeled peptides and peptide mimetics.
    Type: Grant
    Filed: March 1, 2000
    Date of Patent: June 26, 2001
    Assignee: Glaxo Group Limited
    Inventors: William J. Dower, Ronald W. Barrett, Steven E. Cwirla, Christian M. Gates, Peter J. Schatz, Palaniappan Balasubramanian, Christopher R. Wagstrom, Richard Wayne Hendren, Randolph B. Deprince, Surekha Podduturi, Qun Yin
  • Patent number: 6156511
    Abstract: A random peptide library constructed by transforming host cells with a collection of recombinant vectors that encode a fusion protein comprised of a DNA binding protein and a random peptide and also encode a binding site for the DNA. binding protein can be used to screen for novel ligands. The screening method results in the formation of a complex comprising the fusion protein bound to a receptor through the random peptide ligand and to the recombinant DNA vector through the DNA binding protein.
    Type: Grant
    Filed: January 21, 1998
    Date of Patent: December 5, 2000
    Assignee: Affymax Technologies N.V.
    Inventors: Peter J. Schatz, Millard G. Cull, Jeff F. Miller, Willem Peter Christiaan Stemmer, Christian M. Gates
  • Patent number: 6121238
    Abstract: Described are peptides and peptide mimetics that bind to and activate the thrombopoietin receptor. Such peptides and peptide mimetics are useful in methods for treating hematological disorders and particularly, thrombocytopenia resulting from chemotherapy, radiation therapy, or bone marrow transfusions as well as in diagnostic methods employing labeled peptides and peptide mimetics.
    Type: Grant
    Filed: February 3, 1999
    Date of Patent: September 19, 2000
    Assignee: Glaxo Wellcome Inc.
    Inventors: William J. Dower, Ronald W. Barrett, Steven E. Cwirla, Christian M. Gates, Peter J. Schatz, Palaniappan Balasubramanian, Christopher R. Wagstrom, Richard Wayne Hendren, Randolph B. Deprince, Surekha Podduturi, Qun Yin
  • Patent number: 6083913
    Abstract: Receptors are peptides and peptide mimetics that bind to and activate the thrombopoietin receptor. Such peptides and peptide mimetics are useful in methods for treating hematological disorders and particularly, thrombocytopenia resulting from chemotherapy, radiation therapy, or bone marrow transfusions as well as in diagnostic methods employing labeled peptides and peptide mimetics.
    Type: Grant
    Filed: December 4, 1997
    Date of Patent: July 4, 2000
    Assignee: Glaxo Wellcome Inc.
    Inventors: William J. Dower, Ronald W. Barrett, Steven E. Cwirla, David J. Duffin, Christian M. Gates, Sherril S. Haselden, Larry C. Mattheakis, Peter J. Schatz, Christopher R. Wagstrom, Nicholas C. Wrighton
  • Patent number: 5958703
    Abstract: The invention provides methods for screening libraries of complexes for compounds having a desired property, especially, the capacity to agonize, bind to, or antagonize a cellular receptor. The complexes in such libraries comprise a compound under test, a tag recording at least one step in synthesis of the compound, and a tether susceptible to modification by a reporter molecule. Modification of the tether is used to signify that a complex contains a compound having a desired property. The tag can be decoded to reveal at least one step in the synthesis of such a compound.
    Type: Grant
    Filed: December 3, 1996
    Date of Patent: September 28, 1999
    Assignee: Glaxo Group Limited
    Inventors: William J. Dower, Gregory L. Heinkel, Larry Mattheakis, Peter J. Schatz
  • Patent number: 5932433
    Abstract: Biotinylation peptides can be fused to other peptides or proteins of interest using recombinant DNA techniques to provide efficient methods for biotinylating the resulting fusion proteins in vivo or in vitro.
    Type: Grant
    Filed: October 28, 1997
    Date of Patent: August 3, 1999
    Assignee: Affymax Technologies N.V.
    Inventor: Peter J. Schatz
  • Patent number: 5874239
    Abstract: Biotinylation peptides can be fused to other peptides or proteins of interest using recombinant DNA techniques to provide efficient methods for biotinylating the resulting fusion proteins in vivo or in vitro.
    Type: Grant
    Filed: July 15, 1996
    Date of Patent: February 23, 1999
    Assignee: Affymax Technologies N.V.
    Inventor: Peter J. Schatz
  • Patent number: 5869451
    Abstract: Described are peptides and peptide mimetics that bind to and activate the thrombopoietin receptor. Such peptides and peptide mimetics are useful in methods for treating hematological disorders and particularly, thrombocytopenia resulting from chemotherapy, radiation therapy, or bone marrow transfusions as well as in diagnostic methods employing labeled peptides and peptide mimetics.
    Type: Grant
    Filed: December 11, 1996
    Date of Patent: February 9, 1999
    Assignee: Glaxo Group Limited
    Inventors: William J. Dower, Ronald W. Barrett, Steven E. Cwirla, Christian M. Gates, Peter J. Schatz, Palaniappan Balasubramanian, Christopher R. Wagstrom, Richard Wayne Hendren, Randoph B. DePrince, Surekha Podduturi, Qun Yin
  • Patent number: 5733731
    Abstract: A random peptide library constructed by transforming host cells with a collection of recombinant vectors that encode a fusion protein comprised of a DNA binding protein and a random peptide and also encode a binding site for the DNA binding protein can be used to screen for novel ligands. The screening method results in the formation of a complex comprising the fusion protein bound to a receptor through the random peptide ligand and to the recombinant DNA vector through the DNA binding protein.
    Type: Grant
    Filed: October 26, 1995
    Date of Patent: March 31, 1998
    Assignee: Affymax Technologies N.V.
    Inventors: Peter J. Schatz, Millard G. Cull, Jeff F. Miller, Willem Peter Christiaan Stemmer, Christian M. Gates
  • Patent number: 5723584
    Abstract: Biotinylation peptides can be fused to other peptides or proteins of interest using recombinant DNA techniques to provide efficient methods for biotinylating the resulting fusion proteins in vivo or in vitro.
    Type: Grant
    Filed: February 3, 1995
    Date of Patent: March 3, 1998
    Assignee: Affymax Technologies N.V.
    Inventor: Peter J. Schatz
  • Patent number: 5683983
    Abstract: Described are peptides and peptide mimetics that bind to and the IL-5 receptor. Such peptides and peptide mimetics are useful in methods for treating disorders that involve improper production of or response to IL-5 and or the production and accumulation of eosinophils, such as asthma, as well as in diagnostic methods employing labeled peptides and peptide mimetics.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: November 4, 1997
    Assignee: Glaxo Group Limited
    Inventors: Ronald W. Barrett, Bruce P. England, Peter J. Schatz, Derek Sloan, Min-Jia Chen
  • Patent number: 5677280
    Abstract: Described are peptides and peptide mimetics that bind to and the IL-5 receptor. Such peptides and peptide mimetics are useful in methods for treating disorders that involve improper production of or response to IL-5 and or the production and accumulation of eosinophils, such as asthma, as well as in diagnostic methods employing labeled peptides and peptide mimetics.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: October 14, 1997
    Assignee: Glaxo Group Limited
    Inventors: Ronald W. Barrett, Bruce P. England, Peter J. Schatz, Derek Sloan, Min-Jia Chen
  • Patent number: 5668110
    Abstract: Described are peptides and peptide mimetics that bind to and the IL-5 receptor. Such peptides and peptide mimetics are useful in methods for treating disorders that involve improper production of or response to IL-5 and or the production and accumulation of eosinophils, such as asthma, as well as in diagnostic methods employing labeled peptides and peptide mimetics.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: September 16, 1997
    Assignee: Affymax Technologies N.V.
    Inventors: Ronald W. Barrett, Bruce P. England, Peter J. Schatz, Derek Sloan, Min-Jia Chen